AFT Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 2/6

AFT Pharmaceuticals ha aumentado sus beneficios a una tasa media anual de 35.6%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 41.5% anual. Los ingresos han ido creciendo a una tasa media de 14.4% al año. La rentabilidad financiera de AFT Pharmaceuticals es de 14.8%, y sus márgenes netos son de 6.3%.

Información clave

35.6%

Tasa de crecimiento de los beneficios

35.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	35.6%
Tasa de crecimiento de los ingresos	14.4%
Rentabilidad financiera	14.8%
Margen neto	6.3%
Última actualización de beneficios	30 Sep 2023

Actualizaciones de resultados anteriores recientes

Recent updates

We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

Jul 30

With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Jun 02

Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

Mar 20

A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Feb 13

Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Jan 23

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

Jan 02

Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?

Dec 12

AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 21

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero AFT Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NZSE:AFT Ingresos, gastos y beneficios (NZD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Sep 23	175	11	56	5
30 Jun 23	166	11	53	4
31 Mar 23	157	11	49	4
31 Dec 22	149	14	46	4
30 Sep 22	141	17	42	4
30 Jun 22	135	18	40	4
31 Mar 22	130	20	38	4
31 Dec 21	125	15	38	3
30 Sep 21	120	11	39	3
30 Jun 21	116	9	38	2
31 Mar 21	113	8	37	2
31 Dec 20	110	5	36	1
30 Sep 20	107	3	36	0
30 Jun 20	107	7	37	0
31 Mar 20	106	12	37	0
31 Dec 19	100	11	36	0
30 Sep 19	94	11	35	1
30 Jun 19	89	4	35	1
31 Mar 19	85	-3	35	1
31 Dec 18	84	-7	38	2
30 Sep 18	83	-11	40	4
30 Jun 18	82	-12	39	5
31 Mar 18	81	-14	39	7
31 Dec 17	79	-14	37	8
30 Sep 17	76	-14	34	10
30 Jun 17	73	-16	34	10
31 Mar 17	69	-18	34	9
31 Dec 16	67	-18	33	8
30 Sep 16	64	-18	32	8
30 Jun 16	64	-16	30	7
31 Mar 16	64	-13	29	6
31 Dec 15	63	-13	27	5
30 Sep 15	62	-13	26	4
30 Jun 15	59	-13	25	4
31 Mar 15	56	-13	24	5
31 Mar 14	49	-1	16	2

Ingresos de calidad: AFT tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(6.3%) de AFT son inferiores a los del año pasado (12.2%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: AFT ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de 35.6% al año.

Acelerando crecimiento: AFT ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: AFT tuvo un crecimiento negativo de los beneficios (-36.3%) durante el año pasado, lo que dificulta la comparación con la media de la industria Pharmaceuticals (3.4%).

Rentabilidad financiera

Alta ROE: La rentabilidad financiera de AFT (14.8%) se considera baja.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

AFT Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Información clave

Actualizaciones de resultados anteriores recientes

AFT Pharmaceuticals Limited to Report First Half, 2024 Results on Nov 23, 2023

AFT Pharmaceuticals Limited to Report Fiscal Year 2023 Results on May 22, 2023

First half 2023 earnings released: EPS: NZ$0.01 (vs NZ$0.04 in 1H 2022)

AFT Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 24, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

AFT Pharmaceuticals Limited to Report Fiscal Year 2022 Results on May 23, 2022

Recent updates

Price target decreased by 22% to NZ$3.70

Consensus EPS estimates fall by 12%, revenue upgraded

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited Reaffirms Earnings Guidance for the Fiscal Year 2024

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited to Report First Half, 2024 Results on Nov 23, 2023

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Announces Board Changes

Independent Non-Executive Director recently sold NZ$109k worth of stock

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023

Consensus EPS estimates fall by 17%

Does AFT Pharmaceuticals (NZSE:AFT) Deserve A Spot On Your Watchlist?

AFT Pharmaceuticals Limited Provides Earnings Guidance for the Year Ending March 2024

AFT Pharmaceuticals Limited to Report Fiscal Year 2023 Results on May 22, 2023

Price target decreased to NZ$4.22

Consensus forecasts updated

First half 2023 earnings released: EPS: NZ$0.01 (vs NZ$0.04 in 1H 2022)

Is Now The Time To Put AFT Pharmaceuticals (NZSE:AFT) On Your Watchlist?

Price target decreased to NZ$5.51

AFT Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 24, 2022

AFT Pharmaceuticals Limited Update on Maxigesic IV Us Registration Filing

AFT Pharmaceuticals Limited Completes Pascomer Clinical Study

Dr. Doug Wilson to Step Down from AFT Pharmaceuticals Board

US FDA Seeks More Information on AFT Pharmaceuticals Limited's Maxigesic IV Application

Price target decreased to NZ$4.40

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 05, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Should You Be Adding AFT Pharmaceuticals (NZSE:AFT) To Your Watchlist Today?

Investor sentiment improved over the past week

AFT Pharmaceuticals Limited Provides Earnings Guidance for the Year to 31 March 2023

AFT Pharmaceuticals Limited to Report Fiscal Year 2022 Results on May 23, 2022

Price target increased to NZ$5.88

AFT Pharmaceuticals Announces US Food and Drug Administration Approve Topical Treatment Indicated for Facial Angiofibroma

Independent Director recently bought NZ$66k worth of stock

Independent Director recently bought NZ$171k worth of stock

AFT Pharmaceuticals Limited Welcomes Australian Federal Court Appeal Success

Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?

First half 2022 earnings released: EPS NZ$0.04 (vs NZ$0.01 in 1H 2021)

Price target increased to NZ$5.88

We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

AFT Pharmaceuticals Got First Regulatory Approval of Maxigesic Oral Liquid in Europe

With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Full year 2021 earnings released

AFT Pharmaceuticals Limited Announces Earnings Guidance for the Fiscal Year 2022

CFO & Company Secretary exercised options to buy NZ$205k worth of stock.

Consensus EPS estimates fall to NZ$0.092

Price target decreased to NZ$4.95

AFT Pharmaceuticals Revises Earnings Guidance for the Year to 31 March 2021

Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

AFT Pharmaceuticals Signs an Exclusive Maxigesic IV Licensing Agreement for Eight New European Markets

New 90-day low: NZ$4.21

A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

New 90-day high: NZ$5.51

AFT Pharmaceuticals Limited Appoints Anita Baldauf as Non-Executive Director

New 90-day low: NZ$4.55

Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?

Analysts lower EPS estimates to NZ$0.11

AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Revenue and earnings miss expectations

AFT Pharmaceuticals Limited Appoints Eddie Townslie as the Local Director of AFT Pharmaceuticals Europe

New 90-day high: NZ$5.46

AFT Pharmaceuticals Receives a US Food and Drug Administration Complete Response Letter Covering Its Application for the Approval of A Tablet Version of Its Maxigesic® Pain Relief Medication

AFT Pharmaceuticals Limited and Setek Sign Supply Agreement

AFT Pharmaceuticals Limited Appoints Anita Baldauf as a Non-Executive Director

AFT Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 19, 2020

New 90-day high - NZ$4.75

Desglose de ingresos y gastos
Beta